Baike Biotech: Influenza Viral Split Vaccine Clinical Trial Application Approved.

Bekken Biotech announced on the evening of June 19 that the company recently received the "Drug Clinical Trial Approval Notice" for influenza virus split vaccine issued by the National Medical Products Administration. The company has been approved to conduct clinical trials for the prevention of epidemic influenza caused by various types of influenza viruses. If the vaccine can be successfully developed, it will further improve the company's influenza vaccine research pipeline, providing new vaccination options for people aged 60 and above, and expanding the coverage of the company's influenza vaccine to a wider population.